Navigation Links
TGen-led team is 1 of 7 selected for $1 million skin-cancer grants

PHOENIX, Ariz. Aug. 1, 2009 An international scientific team led by the Translational Genomics Research Institute (TGen) has received a $1 million grant to study skin cancer from the Melanoma Research Alliance.

The grant was made to a team led by Dr. Jeffrey Trent, TGen's President and Research Director, who is the Team Lead among the Principal Investigators in the two-year study: Identification of Novel Melanoma Risk Genes Using High-throughput Genomics.

"The world-wide team of investigators on this project has worked together for a decade to identify individuals and families who are at increased risk for this deadly disease. While the team includes investigators from Europe and Australia, the research is particularly important to Arizonans who are disproportionately affected,'' Dr. Trent said.

Dr. Kevin Brown, an Associate Investigator in TGen's Integrated Cancer Genomics Division, also described the TGen-led team as part of an ongoing collaboration with the International Melanoma Genetics Consortium (GenoMEL), which has identified families worldwide that are predisposed to getting skin cancer.

"There are situations in which there is a strong family history of melanoma. If you can identify the genes, or mutations, that put people at risk for melanoma, you can implement targeted screening or prevention efforts,'' Dr. Brown said.

"Identifying the genes that mediate development of melanoma will give you an understanding of the basic biology, and conceivably could give you some clues into ways that you could do chemo prevention, or other things, for people who are at strong risk of getting melanoma,'' Dr. Brown said.

The other Principal Investigators in the TGen-led research are: Dr. Nicolas Hayward of the Queensland (Australia) Institute of Medical Research; Dr. Goran Jonsson of Lund (Sweden) University; and Dr. Graham Mann of the University of Sydney (Australia).

Arizona's non-Hispanic Caucasian population has among the nation's highest incidence rate of skin cancer. Australia has the highest incidence rate of the disease in the world.

The TGen-led team was one of seven multidisciplinary groups who received a total of $6.9 million in awards June 30 from the Washington, D.C.-based Melanoma Research Alliance (MRA) to pursue novel, outcomes-driven melanoma research.

These awards are part of the MRA's second round of grants focused on research that addresses gaps in translational science. In its second year of grant-making, MRA is now supporting 37 of the most promising melanoma research programs worldwide, totaling more than $16 million (including $6.9 million awarded July 30) in an effort to accelerate progress toward a cure.

"We are energized by the quality of proposals we continue to receive from the melanoma research community. In this latest round of grants, we are pleased to support seven multidisciplinary approaches that hold great potential to advance melanoma treatments," said Dr. Suzanne Topalian, M.D., Chair of the MRA Grant Review Committee and Director of the Johns Hopkins Melanoma Program.

According to the grant description presented by Dr. Trent:

"Early detection of cutaneous malignant melanoma offers the best form of cure. Characterization of the genes influencing melanoma risk is critical towards efforts aimed at disease prevention and early detection.

"Studies of families with multiple melanoma patients have identified mutations in two genes that strongly predispose to the disease, but these mutations are found only in a minority of families.

"To identify additional genes, the International Melanoma Genetics Consortium (GenoMEL) recently completed the largest genetic study of melanoma families to date, comprising 174 families with three or more melanoma patients. This study identified two chromosome positions likely to harbor melanoma susceptibility genes, while a separate smaller study by a GenoMEL member group has identified a third.

"We propose here to extend this collaborative effort by screening all genes at these three chromosomal locations for disease-predisposing mutations in melanoma families. We will also work towards identifying additional susceptibility genes by sequencing the entire genomes of patients from five of the largest melanoma families.

"The identification of novel predisposition genes is a major first step towards accurately estimating individualized disease risk and ultimately implementing disease prevention and early-detection strategies for at-risk individuals. Further, characterization of the molecular mechanisms underlying melanoma susceptibility may lead to a better understanding of the processes underlying melanoma development and progression, and ultimately to novel strategies for melanoma treatment."

The other teams receiving the latest round of MRA grants are:

Developing Melanoma Screening in Primary Care
Principal Investigators:
Team Lead: Martin A. Weinstock, M.D., Ph.D., Rhode Island Hospital and Brown University
Maryam Asgari, M.D., M.P.H., Kaiser Foundation Research Institute
Melody Eide, M.D., M.P.H., Henry Ford Health System
Suzanne Fletcher, M.D., M.Sc., Harvard Pilgrim Health Care and Harvard Medical School
Alan Geller, R.N., M.P.H., Harvard School of Public Health
Allan Halpern, M.D., M.S., Memorial Sloan-Kettering Cancer Center

Manipulating Immune Regulation in Adoptive T-cell Therapy for Melanoma Principal Investigators:
Team Lead: Jeffrey Weber, M.D., Ph.D., H. Lee Moffitt Cancer Center and Research Institute
Patrick Hwu, M.D., M.D. Anderson Cancer Center

Identification and Validation of Combination Therapies for Melanomas
Principal Investigators:
Team Lead: Michael J. Weber, Ph.D., University of Virginia
Levi Garraway, M.D., Ph.D., Dana-Farber Cancer Institute
Dan Gioeli, Ph.D., University of Virginia

Proposal Title: Sequencing of the Melanoma Exome, Transcriptome and Epigenome Principal Investigators:
Team Lead: Ruth Halaban, Ph.D., Yale University
Marcus Bosenberg, M.D., Ph.D., Yale University
Michael Krauthammer, M.D., Ph.D., Yale University
David Stern, Ph.D., Yale University

Combinatorial Immunotherapy for Melanoma with B7-H1/PD-1 Checkpoint Blockade
Principal Investigators:
Team Lead: Drew Pardoll, M.D., Ph.D., Johns Hopkins University
Lieping Chen, M.D., Ph.D., Johns Hopkins University
Suzanne Topalian, M.D., Johns Hopkins University

Identification of Novel Melanoma Risk Genes Using High-throughput Genomics Principal Investigators:
Team Lead: Jeffrey Trent, Ph.D., Translational Genomics Research Institute
Nicolas Hayward, Ph.D., Queensland Institute of Medical Research
Goran Jonsson, Ph.D., Lund University
Graham Mann, Ph.D., The University of Sydney

Defining the Importance of Immunity to NY-ESO-1 in Melanoma
(Co-funded by the Cancer Research Institute)
Principal Investigators:
Team Lead: Jedd D. Wolchok, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center
James P. Allison, Ph.D., Memorial Sloan-Kettering Cancer Center
Jonathan Cebon, Ph.D., Ludwig Institute for Cancer Research
Alexander Eggermont, M.D., Ph.D., Daniel den Hoed Cancer Center
Sacha Gnjatic, Ph.D., Ludwig Institute for Cancer Research
Dirk Jger, M.D., University Hospital Heidelberg
Elke Jger, Ph.D., Goethe University Frankfurt
Alexander Knuth, M.D., University of Zurich
Lloyd J. Old, M.D., Ludwig Institute for Cancer Research


Contact: Steve Yozwiak
The Translational Genomics Research Institute

Related medicine news :

1. Brooke Franchise Corporation Announces Selected July Results
2. Corbett Selected to Host the Only Midwest Global Awards Judging Competition
3. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
4. Crdentia Selected by High Rock Raceway to Provide Healthcare Staffing Services
5. Fry Construction Selected for High-Profile Medical Imaging Project
6. Meth Project Advertisements Selected for National Prevention Campaign
7. Eight Graduate Nursing Students Selected to Receive The California Endowment-AACN Minority Nurse Faculty Scholarship
8. CutisPharma Selected by Medicine Shoppe International as Preferred Vendor for Unit-of-Use Compounding Kits
9. SAIC Selected to Support the U.S. Military Theater Medical Information Program-Joint
10. The Cooper Institutes FITNESSGRAM Selected as Statewide Physical Fitness Assessment Tool
11. CBaySystems Selected to Receive Deloittes 2007 Maryland Technology Fast 50 Award
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published ... Toronto and the University of British Columbia suggested that laws requiring bicyclists to wear ... explains that part of the reason for the controversial conclusion is that, while helmets ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the toilets were," said an inventor from Hillside, N.J. "Many people catch diseases ... cover so that individuals will always be protected from germs." , He developed ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... of progress through sharing, the 2016 Building Better Radiology Marketing Programs ... will begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to ... Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored ... one of twelve colleges and universities in the state of California make the cut. ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... abuse located in central Michigan, have come together on Thanksgiving Day to share ... video, available for viewing on the Serenity Point YouTube channel, patients displayed what ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... YORK , November 27, 2015 ... system is set to go online. The potential to ... processes is vast and far from fully exploited as ... to patient health records, either via mobile tablet or ... ) --> ) --> ...
(Date:11/27/2015)... ) ... "2016 Global Tumor Marker Testing Market: Supplier ... Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive ... offering. --> ) has ... Global Tumor Marker Testing Market: Supplier Shares ...
(Date:11/26/2015)... Netherlands , November 26, 2015 ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... Netherlands has found that immunotherapy can be ...
Breaking Medicine Technology: